A Phase 4 interventional study of somatropin and somatropin in Genetic Disorder and Turner Syndrome, sponsored by Novo Nordisk A/S. Completed at 1 site in Netherlands. Open to female participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-01-18.
Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing Human Growth Hormone in Turner Syndrome — none open to participants now, none under way, none of them phase 3. Human Growth Hormone · Turner Syndrome.
Among the 14 studies testing Human Growth Hormone in Turner Syndrome, this one is the 10th largest by enrollment, is one of 2 that started in 1989, is one of 6 in phase 4, and was the 10th registered.
125 studies on the registry are indexed under Turner Syndrome; 33 are open to participants now.
Browse Turner Syndrome studies →None of the 14 studies testing Human Growth Hormone in Turner Syndrome is open now. The open studies under Turner Syndrome, anywhere →
Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 25 Turner Syndrome studies recruiting now, 8 (32%) set no upper age limit and 14 (56%) stop at 75 or younger; 15 take children under 18; 5 take healthy volunteers.
This study: 2 Years to 11 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 1987; this study’s year is marked. 2 started in 1989.
This study's enrollment of 65 is close to the median of 67 across 52 interventional studies indexed under Turner Syndrome.
Median enrollment 108 across the 14 interventional studies. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 8 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
12 studies in Turner Syndrome by Novo Nordisk A/S: none open now, 2 under way, 2 of them phase 3. Of 10 finished, 1 (10%) have results posted.
Among the 12 studies in Turner Syndrome by Novo Nordisk A/S, this one is the only one that started in 1989, is one of 3 in phase 4, and was the 4th registered.
Novo Nordisk A/S’s Turner Syndrome studies by the year they started, since 1987.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing Human Growth Hormone in Turner Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 12 in Turner Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Europe. The aim of this trial is to assess whether increasing doses of somatropin (Norditropin®) can maintain the initial increase in height velocity and improve final height. This trial has two trial periods, a main period of 4 years and an extension period until final height is reached.
125 studies on the registry are indexed under Turner Syndrome; 33 are open to participants now.
This study's enrollment of 65 is close to the median of 67 across 52 interventional studies indexed under Turner Syndrome.
Browse Turner Syndrome studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Turner Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Genetic Diseases, Inborn. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: somatropin · Drug: oestrogen
Drug: somatropin · Drug: oestrogen
Drug: somatropin · Drug: oestrogen
4 IU/m\^2 body surface for 4 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
Initial dose 4 IU/m\^2 body surface the first year, then 6 IU/m\^2 body surface for 3 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
Initial dose 4 IU/m\^2 body surface the first year, then 6 IU/m\^2 body surface, the second year and finally 8 IU/m\^2 body surface for 2 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
Treatment with oestrogen was administered if spontaneous puberty had not occurred by age 12 years and was initiated in the extension period after at least four years of somatropin treatment
Final height
Height velocity (cm/year)
Ratio between change in bone age and change in chronological age
Age at onset of puberty
Adverse events
The record gives a start of Nov 1989, a primary completion of Sep 2003 and a completion of Sep 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone